UPA MAGTIDELIRA 33 (Maglutide 33mg) Pre-Filled Pen | Research Peptide
UPA Magtidelira 33 mg — Pre-Filled Pen
Metabolic Research | GLP-1 & GIP Signalling | Appetite Regulation
Product Overview
UPA Magtidelira 33 mg is a pre-filled pen-format product marketed as a hybrid formulation containing tirzepatide and semaglutide, with a labelled total strength of 33 mg.
Tirzepatide acts on two metabolic hormone receptors, GIP and GLP-1, while semaglutide selectively activates the GLP-1 receptor. These pathways are involved in appetite signalling, blood-glucose regulation and energy balance.
Both compounds have been extensively studied in clinical research, particularly in relation to type 2 diabetes and weight management. However, their combination in a single product is a separate formulation that requires its own evidence of safety, quality and efficacy.
Key Clinical Research Findings
1. Body-Weight Reduction
In the 72-week SURMOUNT-1 trial, average body-weight reductions with tirzepatide were 15.0%, 19.5% and 20.9% across the three studied dose groups.
In the 68-week STEP 1 trial, semaglutide 2.4 mg produced an average body-weight reduction of approximately 14.9%, compared with 2.4% with placebo.
These results demonstrate the potential of the individual medicines in their studied populations. They are not predictions of weight loss from Magtidelira.
2. Appetite Regulation
Tirzepatide and semaglutide influence incretin pathways involved in appetite and food intake. Clinical studies of their respective authorised formulations have demonstrated meaningful effects on body weight.
However, there is insufficient clinical evidence to conclude that combining both compounds produces greater appetite control or superior weight-loss outcomes.
3. Blood-Glucose Regulation
Both medicines have demonstrated improvements in blood-glucose control in clinical trials involving people with type 2 diabetes. Tirzepatide's dual GIP/GLP-1 receptor activity and semaglutide's GLP-1 receptor activity have been studied in their respective authorised formulations.
These findings cannot establish the efficacy or safety of an unverified combination product.
4. Metabolic Health Research
Clinical trials of tirzepatide and semaglutide have examined changes in body weight and several cardiometabolic markers. The findings have contributed to significant scientific interest in incretin-based treatments for metabolic health.
The extent to which these outcomes apply to Magtidelira is unknown without appropriate product-specific clinical evidence.